Possibility to use attenuated Hepatitis A virus vaccine as anticancer agent against liver cancer Attenuated Hepatitis A Vaccine as a Potential Lever Cancer Therapy
Article Sidebar
Main Article Content
Abstract
Attenuated viral vaccines that originally developed for infectious disease prevention, have established potential in cancer therapy by selectively infecting and lysing tumor cells while stimulating anti-tumor immune responses. Current work aims to try the In Vitro Immuno-Independent experiments for discover the anti-tumor activity of live attenuated Hepatitis A virus vaccine (LAHAVV) against rat hepatocellular Carcinoma (HC) Cancer cell line as well as against Rat Embryonic fibroblast (REF) Cell line as normal cells. Six concentrations of LAHAVV [35, 30, 25, 20, 15 and 10 viral particle per microliter (V/ µl)] were tested against both cancer (HC) and normal (REF) cell lines. Using the Crystal Violate Cytotoxicity Assay. Cells killing percentages were assessed for each of the six concentrations of vaccine, thus vaccine Ic50 were calculated. Cytopathological effects such apoptotic cells were evaluated under an inverted microscope. With significant statistical differences at a probability level lower than 0.01. The results found a toxic effect of LAHAVV on all HC cancer cell line, while for the normal REF cell line, this toxic effect was correlated only with the highest concentrations of vaccine. Moreover, the study explored that the multiplicity of infection (MOI) of LAHAVV against cancer cell was greater than its MOI against normal cell (2.5 vs 1). Cytological changes were observed in cancer cells that have been treated by LAHAVV with insignificant effect on non-cancer (normal) cells.
Article Details
This work is licensed under a Creative Commons Attribution-ShareAlike 4.0 International License.
The Journal of Medical and Oral Biosciences uses a Creative Commons Attribution (CC Attribution-ShareAlike 4.0) and its license of (CC BY-SA 4.0). This license allows the authors to hold ownership of the copyright of their articles.
Attribution-Share Alike 4.0 International License (CC BY-SA 4.0). 
Under the CC BY-SA 4.0 the authors are free to:
Share — copy and redistribute the material in any medium or format for any purpose, even commercially.
Adapt — remix, transform, and build upon the material for any purpose, even commercially.
The licensor cannot revoke these freedoms as long as you follow the license terms.
Under the following terms:
Attribution — You must give appropriate credit, provide a link to the license, and indicate if changes were made. You may do so in any reasonable manner, but not in any way that suggests the licensor endorses you or your use.
ShareAlike — If you remix, transform, or build upon the material, you must distribute your contributions under the same license as the original.
No additional restrictions — You may not apply legal terms or technological measures that legally restrict others from doing anything the license permits.
No use, distribution or reproduction is permitted which does not comply with these terms.
https://creativecommons.org/licenses/by-sa/4.0/
References
1. Llovet, Josep M., et al. "Immunotherapies for hepatocellular carcinoma." Nature reviews Clinical oncology 19.3 (2022): 151–172. https://zaruku.ru/rak-pecheni/kakie-byvayut-vidy-sistemnoj-terapii-raka-pecheni/
2. McGlynn KA, Petrick JL, El-Serag HB. Epidemiology of Hepatocellular Carcinoma. Hepatology. 2021 Jan;73 Suppl 1(Suppl 1):4-13. doi: 10.1002/hep.31288. Epub 2020 Nov 24. PMID: 32319693; PMCID: PMC7577946.
3. Bruix J, Gores GJ, Mazzaferro V. Hepatocellular carcinoma: clinical frontiers and perspectives. Gut. 2014 May;63(5):844-55. doi: 10.1136/gutjnl-2013-306627. Epub 2014 Feb 14. PMID: 24531850; PMCID: PMC4337888.
4. Qasim AJ, Abood AK, Al-Shammari AM. Investigating the Anticancer Properties of Bacterial Toxoid in Combination Vaccines. Asian Pac J Cancer Prev. 2025 Jan 1;26(1):233-238. doi: 10.31557/APJCP.2025.26.1.233. PMID: 39874006; PMCID: PMC12082433.
5. Craig AS, Schaffner W. Prevention of hepatitis A with the hepatitis A vaccine. N Engl J Med. 2004 Jan 29;350(5):476-81. doi: 10.1056/NEJMcp031540. Erratum in: N Engl J Med. 2004 Jun 24;350(26):2726. PMID: 14749456.
6. S A JarAllah and Z S Al-Garawi 2021 J. Phys.: Conf. Ser. 1853 012063. DOI: 10.1088/1742-6596/1853/1/012063
7. Torres HA, Shigle TL, Hammoudi N, Link JT, Samaniego F, Kaseb A, Mallet V. The oncologic burden of hepatitis C virus infection: A clinical perspective. CA Cancer J Clin. 2017 Sep;67(5):411-431. doi: 10.3322/caac.21403. Epub 2017 Jul 6. PMID: 28683174; PMCID: PMC5591069.
8. Ramsey SD, Unger JM, Baker LH, Little RF, Loomba R, Hwang JP, Chugh R, Konerman MA, Arnold K, Menter AR, Thomas E, Michels RM, Jorgensen CW, Burton GV, Bhadkamkar NA, Hershman DL. Prevalence of Hepatitis B Virus, Hepatitis C Virus, and HIV Infection Among Patients With Newly Diagnosed Cancer From Academic and Community Oncology Practices. JAMA Oncol. 2019 Apr 1;5(4):497-505. doi: 10.1001/jamaoncol.2018.6437. Erratum in: JAMA Oncol. 2019 Apr 1;5(4):579. doi: 10.1001/jamaoncol.2019.0220. PMID: 30653226; PMCID: PMC6459217.
9. Macedo de Oliveira A, White KL, Leschinsky DP, Beecham BD, Vogt TM, Moolenaar RL, Perz JF, Safranek TJ. An outbreak of hepatitis C virus infections among outpatients at a hematology/oncology clinic. Ann Intern Med. 2005 Jun 7;142(11):898-902. doi: 10.7326/0003-4819-142-11-200506070-00007. PMID: 15941696.
10. Cohen JI, Rosenblum B, Ticehurst JR, Daemer RJ, Feinstone SM, Purcell RH. Complete nucleotide sequence of an attenuated hepatitis A virus: comparison with wild-type virus. Proc Natl Acad Sci U S A. 1987 Apr;84(8):2497-501. doi: 10.1073/pnas.84.8.2497. PMID: 3031686; PMCID: PMC304679.
11. Mustafa M, Ahmad R, Tantry IQ, Ahmad W, Siddiqui S, Alam M, Abbas K, Moinuddin, Hassan MI, Habib S, Islam S. Apoptosis: A Comprehensive Overview of Signaling Pathways, Morphological Changes, and Physiological Significance and Therapeutic Implications. Cells. 2024 Nov 6;13(22):1838. doi: 10.3390/cells13221838. PMID: 39594587; PMCID: PMC11592877.
12. Moyer A, Tanaka K, Cheng EH. Apoptosis in Cancer Biology and Therapy. Annu Rev Pathol. 2025 Jan;20(1):303-328. doi: 10.1146/annurev-pathmechdis-051222-115023. PMID: 39854189.
13. Flusberg DA, Sorger PK. Surviving apoptosis: life-death signaling in single cells. Trends Cell Biol. 2015 Aug;25(8):446-58. doi: 10.1016/j.tcb.2015.03.003. Epub 2015 Apr 25. PMID: 25920803; PMCID: PMC4570028.
14. Wei MC, Lindsten T, Mootha VK, Weiler S, Gross A, Ashiya M, Thompson CB, Korsmeyer SJ. tBID, a membrane-targeted death ligand, oligomerizes BAK to release cytochrome c. Genes Dev. 2000 Aug 15;14(16):2060-71. PMID: 10950869; PMCID: PMC316859.
15. Llambi F, Moldoveanu T, Tait SW, Bouchier-Hayes L, Temirov J, McCormick LL, Dillon CP, Green DR. A unified model of mammalian BCL-2 protein family interactions at the mitochondria. Mol Cell. 2011 Nov 18;44(4):517-31. doi: 10.1016/j.molcel.2011.10.001. Epub 2011 Oct 27. PMID: 22036586; PMCID: PMC3221787.